Kessler Topaz Meltzer & Check, LLP ("Kessler Topaz") announces an investigation of potential securities fraud claims on behalf of shareholders of Penumbra, Inc. (“Penumbra”) (NYSE: PEN).
Penumbra is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medial conditions in markets.
Kessler Topaz's investigation concerns whether Penumbra’s public statements concerning the safety of its products and its scientific research were false and misleading.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP toll free at 1-844-887-9500 or 1-610-667-7706, or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.